

# Lyophilization – Modern Techniques & New Requirements

the implications

of the New EU GMP Annex 1!

Opportunities and Challenges for the

Pharmaceutical Industry

Part of PharmaCongress 2024

19/20 March 2024

Wiesbaden, Germany

### Highlights

- Annex 1 Impact and Inspection Experience
- Process Validation and ongoing Lifecycle Verification
- Atmospheric & Continuous Freeze Drying
- Lyophilization Technology Design Requirements and Technical Solutions
- Aseptic Lyophilization with the Help of Protective Membrane Bags
- Container Closure Integrity
- Process Simulation / Media Fill
- Aseptic Filling and Lyophilization of Parenterals in RABS
- Improving Sustainability of Pharmaceutical Freeze Drying

### Speakers

Thomas Beutler | GEA, Germany

Francis Carroll | West, Ireland

Dr Tino Galgon | Lyocontract, Germany

**Dr Friedrich Haefele** | Formerly Boehringer Ingelheim Pharma, Germany

Frank Heck | CSL Behring, Germany

**Prof Alf Lamprecht** | University of Bonn, Germany

**Dr Benjamin Ledermann** | GEA, Germany

Rolf Lenhardt | Teclen, Germany

Heide Nagel | Novartis Pharma Stein, Switzerland

Matthias Schaar | Novartis, Switzerland

**Dr Frank Sielaff** | Hessian State Office of Health and Care, Germany

Dr Andrea Weiland-Waibel | ExplicatPharma, Germany







Image: GEA

#### **OBJECTIVES**

Take advantage of the opportunity to focus on freeze drying technologies and processes and get a first-hand demonstration of solutions for diverse requirements. Further, you will learn how the freeze drying output is affected by different equipment, parameter changes, solvents, etc.

#### **BACKGROUND**

Lyophilization (or freeze drying) is one of the most exciting technologies in the pharmaceutical industry, although it is a very old process for the preservation of unstable materials. Trends are growing towards using non-aqueous systems.

Additionally, Process Analytical Technology (PAT) / RTRT (Real Time Release Testing, Annex 17 of the EU GMP Guide) systems for in-line process monitoring are used to control and determine critical processing parameters. PAT plays also an important role in continuous lyophilization processes. According to ICH's new guideline Q13 "continuous manufacturing (CM) has potential for improving the efficiency, agility, and flexibility of drug substance and drug product manufacturing". Regulatory agencies have seen more companies engaged in the development and implementation of CM in recent years than in the past.

Modern QbD (Quality by Design) development following ICH Q8, Q9 and Q10 is based on the objective to design a lyophilization cycle applying a systematic and scientific approach instead of trial

### PROGRAMME 19 March 2024

### Regulatory Overview, Annex 1 Impact and Inspection Experience

Dr Frank Sielaff, Hessian State Office of Health and Care, Germany

- Regulatory framework (EU), impact for Lyo-Products
- Impact of new Annex 1
- Inspection experience

### Process Validation of Lyophilized Products and ongoing Lifecycle Verification

Dr Andrea Weiland, ExplicatPharma

- Critical quality attributes (CQAs) and critical process parameters (CPPs):
  - Assessment of CPPs through robustness testing to establish the process boundaries as the basis for the transfer from lab to commercial scale
- Freeze drying scale-up and validation:
  - Process qualification/validation in lyophilization strategies in relation to FDA/EMA modern process validation guidelines
- Process control strategies:
  - Hot and cold spot determination to allow for process control by using a product temperature PAT device

## Lyophilized Plasma Products - Experience and Technical Challenges in Refrigeration

Frank Heck, CSL Behring

The operator's point of view:

- Freeze technology through the ages
- Freeze drying, but please climate friendly
- Plate cooling and the requirements for technical components in the product environment
- Methodologies for condition-based technical monitoring
- Outlook

#### **Atmospheric Spray Freeze Drying**

Prof Alf Lamprecht, University of Bonn

- Process understanding, monitoring & control
- Design of continuous lyophilization

#### Continuous Freeze Drying

Dr Friedrich Haefele, formerly Boehringer Ingelheim Pharma Freeze drying in Food and Pharma

- Market survey
- Batch process lyophilization
- Applications for continuous lyophilization
- Outlook

### Improving the Sustainability of Pharmaceutical Freeze Drying

Dr Benjamin Ledermann, GEA

Thomas Beutler, GEA

- Natural refrigerants
- Microwave-assisted freeze drying
- Atmospheric spray freeze drying
- Drying time reduction
- GWP reduction



Image: GEA

and error. Sufficient process understanding is essential to achieve a robust production process and efficient handling of post-approval changes (life cycle management according to ICH Q12) of a freeze-drying process.

There is an increasing trend in aseptically produced lyophilized products, including peptides and proteins. Owing to the nature of these biological products, the lyo-cycle is more complicated and, in most cases, even longer than for other medicinal products. The utility of lyophilization goes far beyond the vial. Principles of low temperature, low pressure can be applied to stabilize substances ranging from high potent APIs, novel medical devices, biologics and nanomaterials, freeze drying offers multiple opportunities.

#### **TARGET AUDIENCE**

This conference addresses specialists and executives working in the fields of pharmaceutical manufacture, research and development and quality control, as well as engineers, project/facility engineers, especially those involved in the implementation of new monitoring methods for controlled nucleation, risk-based scale-up models and process technology for freeze drying processes. The conference is also of interest for participants working in the areas of container development and manufacturing process/packaging.

#### **MODERATOR**

Dr Ingrid Walther, Pharma Consulting Walther

### PROGRAMME 20 March 2024

#### Vials and Stoppers for Lyophilization

#### Francis Carroll, West

- Primary packaging aspects for lyophilization
- Considerations for lyo stoppers
- Considerations for lyo vials
- Volatile Extractables
- EU GMP Annex I

#### **Container Closure Integrity**

#### Matthias Schaar, Novartis

- Applicable CCIT and Process Analytical Technologies via non-destructive methodologies
- Examples

#### Aseptic Process Simulation (Media Fill)

Heide Nagel, Novartis Pharma Stein

- Media Fill Design
- Worst-case parameters for Media Fills
- Validation of lyophilization processes with Media Fills
- Requirements for Media Fills
- Trends with regards to Media Fills

### Annex 1 Upgrade of Aseptic Filling and Lyophilization of Parenterals in RABS

Dr Tino Galgon, Lyocontract

- GAP analysis in relation to the new Annex 1
- Risk-based determination of monitoring points for the B area
- Risk-based upgrade of monitoring in the aseptic core zone (RABS)
- Implementation of a new stopper sterilization and drying system
- Integration of a glove lifecycle including testing, cleaning and sterilization

### Aseptic Lyophilization with the Help of Protective Membrane Bags

Rolf Lenhardt, Teclen

- Annex 1 requirements for aseptic lyophilization processes
- Lyophilization protection with membrane technology for vials
- Sterile bagging unit for small sterile batches with open RABS or Isolator
- Are pilot freeze dryer without CIP/SIP suitable for aseptic processing in combination with sterile bagging unit

#### **SPEAKERS**



Thomas Beutler

GEA, Germany

Thomas Beutler holds a Dipl.-Ing. degree in electrical engineering. In the first seven years of his career he

created hardware and software for packing machines. Since 1997 he has been working in the freeze drying business. At that time the company belonged to STERIS. The freeze drying business was then taken over in 2005 by GEA. Since 2008 he was responsible for the process design of GEA Lyophil freeze dryers. In 2012 he also took on the responsibility as head of the project management to build a bridge between the engineering department and the needs of project managers. Since 2016 he has been responsible for the technology management lyophilization of GEA Lyophil.



Francis Carroll

West, Ireland

Francis is a Snr.Technical Account Specialist at West and has almost 20 years' pharmaceutical industry

experience across various disciplines, including Sterile Fill Finish, Lyophilization Scale-up and Optimization, Technology Transfer, and Extractable/Leachables. In his current role, he supports West customers to choose optimized primary packaging components for their drug products and associated ongoing technical support.



**Dr Tino Galgon,** Lyocontract, Germany

Tino is Managing Director of LYOCONTRACT GmbH with more than 20 years of experience in pharma-

ceutical industry. LYOCONTRACT is a specialized CMO for aseptic manufacturing and lyophilisation and is based in Germany.



Dr Friedrich Haefele

Formerly Boehringer Ingelheim Pharma, Germany In May 2006 Friedrich joined Boehringer Ingelheim Pharma where he was responsible for the depart-

ment Biopharma Fill & Finish Germany. Today, he is member of the Pharma Congress Steering Committee.



Frank Heck

CSL Behring, Germany

Frank is currently Process Technology Site Lead at CSL Behring GmbH in Marburg. He has worked at

CSL in various engineering functions since 1999.



Prof Alf Lamprecht

University of Bonn, Germany

Alf Lamprecht has been Professor for Pharmaceutical Technology and Biopharmacy at the University of

Bonn since October 2007. His current work includes the development of continuous atmospheric freeze-drying processes.



Dr Benjamin Ledermann

GEA, Germany

Benjamin joined the GEA Lyophil GmbH as an expert for freeze drying technology in 2018. At GEA he is

involved in the development and evaluation of novel technologies like microwave-assisted freeze drying and controlled nucleation.



Rolf Lenhardt

Teclen, Germany

Rolf is a Process-Engineer by education (Dipl.-Ing. Univ.) and has 15 years of experience in the pharma-

ceutical industry. He is Founder and Managing Director of Teclen GmbH with deep knowledge in protective membrane for lyophilization.



Heide Nagel

Novartis Pharma Stein AG, Switzerland Since 2012 at Novartis Pharma AG, as Senior QA Expert with main focus on QA-Oversight. Currently

within Manufacturing Science & Technology (MS&T) as Senior Process Expert Microbiology, Sterility Assurance responsible to establish microbiological concepts for sterile manufacturing (Microbial Control Strategy).



Matthias Schaar

Novartis, Switzerland

Matthias started his career at Novartis Pharma Stein AG in the Microbiological Department. Since 2012 he is leading the Qualification & Infrastructure team.



Dr Frank Sielaff

GMP Inspector, Germany

Frank is GMP Inspector at the competent authority
of Hessen with focus on inspection of drug manu-

facturers and laboratories in Germany and countries outside of the EU. Before joining the GMP inspectorate Dr Sielaff was several years employed in the pharmaceutical industry as Head of QC and as QP.



Dr Andrea Weiland-Waibel

ExplicatPharma GmbH, Germany
Andrea held several leadership positions within
Pfizer, working as Project Manager in process tech-

nology and being responsible for technology transfer & process development. After joining IDEA AG, a biotechnology company based in Munich, Andrea held the position of Director Pharmaceutical Development. She is founder of Explicat Pharma GmbH and Managing Director since 2005.





The guiding theme of the GMP PharmaCongress 2024 on 19/20 March will be "users sharing challenges and solutions in practice". Therefore, benefit from your colleagues' experience and from the direct information exchange at the GMP PharmaCongress & GMP PharmaTechnica 2024.

#### The Conference Tracks

As a participant you can switch between any of the **11 conference tracks** any time and also visit the PharmaTechnica Expo with more than 110 international exhibitors.

The GMP PharmaCongress Conference Tracks	19 March 2024	20 March 2024
Non-Sterile Products – Challenges in Manufacturing & Quality	<b>✓</b>	n.a.
GMP – Green or Good Manufacturing Practice?	✓	n.a.
Packaging/Packaging Materials – Challenges & Solutions	n.a.	✓
European Aseptic Conference – Technology	✓	✓
Trends in Barrier Systems & Robotics	✓	✓
Modern Cleanroom Technology	✓	✓
Digitalisation & Artificial Intelligence	✓	✓
GMP for Pre-Filled Syringes (PFS)	✓	✓
Lyophilization – Modern Techniques & New Requirements	✓	✓
ATMPs – Hurdles & Achievements in Quality and Safety	✓	✓
Vaccines – Advantages & Challenges in Manufacturing	✓	✓
GMP PharmaTechnica Expo	<b>✓</b>	<b>✓</b>

#### Keynote on 19 March 2024

The CEPI Project – 40 Countries – 1 Billion Euros for Vaccines

Dr Guido Dietrich, CEPI

Do you know the worldwide importance of CEPI? And why is this so important for everyone working in pharmaceutical production? Our first keynote will address a very important new development. More than 40 countries, several non-governmental organizations and the European Commission are involved in the Coalition for Epidemic Preparedness Innovations (CEPI).

#### What is the goal?


The goal of CEPI is to develop, produce and distribute a vaccine as quickly as possible in the event of the next global pandemic, i.e. within 100 days.


#### What is the current budget?

For the first 5 years alone, a budget of one billion euros has been made available.

In the Live Demo Area in the PharmaTechnica Expo hall you will benefit from the exhibitors' demonstrations – presenting their latest technology, products and services. Take advantage of these live performances – and get to feel and experience their products. For a list of all companies exhibiting at PharmaTechnica, please see the exhibitor list and plan on the website at www.pharma-congress.com.

of all companies exhibiting at 1 harmareetimed, please see the exhibitor list and plan of the website at www.pharma congress.com.			
Exhibitor	Stand	Live Demo	
boTec	A 7	TBN	
MKVersuchsanlagen	A 12	TBN	
Ellab	A 16	TBN	
Bausch & Ströbel	A 33	OMNIA - Boost your processes and step closer to your pharmaceutical plant of the future.	
PHARMAPLAN	A 37	Accelerated Design Decisions enabled by Digital Twins	
Quascenta Pte	В 6	Using an Intelligent Lifecycle-Based Solution for Streamlined Product Tracking, Design Optimization, Collaboration, and Reporting	
ZETA	B 12	TBN	
IWT / Tecniplast	B 15	High pressure cleaning in pharmaceutical production. Advantages, challenges, sustainability and savings	
MBV	B 20	TBN	
Emerson Automation Solutions	B 22	TBN	
Atec Steritec	B 28	Safe & Sterile Transfer with Minimal Operator Intervention	
REA Elektronik	B 29	Experts in Printing and Code Verification of pharmaceutical and medical-device packaging (f.e.UDI/MDR)	
Friedrich Sailer	B 31	Shining Solutions: Live Demo of Cutting-Edge Stainless Stell Cleanroom Equipment	
Merck	B 32	Annex 1's "Specific Risks Associated with Single-Use Systems"	
Particle Measuring Systems	C 7	Facility Monitoring Systems	
Yokogawa	C 9	Flow Imaging using FlowCam for High Performance Products to warrant constant excellent Quality	









Congress Dates

Tuesday, 19 March 2024, 09.00 - 18.00 h Wednesday 20 March 2024, 09.00 - 17.00 h Registration

Tuesday & Wednesday, 19/20 March 2024, 08.00 - 09.00 h

#### Fees

The one day ticket is available for € 690,- plus VAT, both days for € 1,380.- plus VAT. It includes participation in any track on that day and the visit of the PharmaTechnica Expo. In addition, lunch and beverages during the tracks

and in breaks as well as the social event on the evening of the first congress day, 19 March is included; please mark if you would like to attend the Social Event. The fee is payable in advance after receipt of invoice.

#### Venue

RheinMain CongressCenter (rmcc) Friedrich-Ebert-Allee 1 | 65189 Wiesbaden Phone: +49 (0) 611 1729-444

E-Mail: veranstaltungsservice-rmcc@wicm.de

#### Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms close to the CongressCenter. You will receive a room reservation form when you have registered for the conference. Reservation should be made directly with the hotel. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Presentations/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event. CONCEPT HEIDELBERG

P.O.Box 10 17 64

69007 Heidelberg, Germany Phone: +49 (0) 62 21 / 84 44-0 | Fax: +49 (0) 62 21 / 84 44 34 info@concept-heidelberg.de | www.concept-heidelberg.de

For questions regarding content please contact: Dr Andrea Kühn-Hebecker (Operations Director) at +49 (0) 62 21 / 84 44 35, or at kuehn@concept-heidelberg.de

For questions regarding organisation please contact: Mr Ronny Strohwald (Organisation Manager) at +49 (0) 62 21 / 84 44 51, or at strohwald@concept-heidelberg.de

If the bill-to-address deviates from the specifications on the right, please fill out here:	Reservation Form (Please complete in full)		
	Lyophilization – Modern Techniques & New Requirements		
	Part of PharmaCongress 2024   19/20 March 2024, Wiesbaden, Germany  Day 1 & 2 (19/20 March 2024) Day 1 (19 March 2024) Day 2 (20 March 2024)		
	Yes, I would also like to take part in the Social Event on the evening of 19 March 2024.		
	□Mr □Ms □Mx □Dr		
	First name, Surname		
	Company		
	Department		
CONCEPT HEIDELBERG P.O. Box 101764 Fax +49 (0) 62 21/84 44 34 D-69007 Heidelberg GERMANY	Important: Please indicate your company's VAT ID Number P.O. Number (if applicable)		
	Street/P.O. Box		
	City Zip Code		
	Country		
	Phone/Fax		
	E-Mail (please fill in)		

soon as possible and will receive a full refund of fees paid.

CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice. Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received

your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of July 2022). German law shall apply. Court of jurisdiction is Heidelberg. Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca\_privacy. html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.